Needham analyst David Saxon has reiterated their neutral stance on GMED stock, giving a Hold rating on July 3.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
David Saxon has given his Hold rating due to a combination of factors impacting Globus Medical’s current performance and future outlook. The company’s recent announcement of a CEO transition has introduced some uncertainty, as the new leadership may bring changes in strategic direction. Additionally, while Globus Medical preannounced second-quarter revenue slightly above consensus, the base business results fell short of expectations, indicating potential challenges in sustaining growth.
Furthermore, despite reiterating its 2025 revenue and earnings per share guidance, there are concerns about the company’s growth trajectory, particularly in its Enabling Technologies segment. The preannouncement suggests that the company’s performance may not fully align with bullish expectations, leading to a cautious stance. As a result, Saxon has opted to maintain a Hold rating, awaiting more comprehensive data from the forthcoming full second-quarter results to reassess the company’s position.
In another report released on July 3, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $65.00 price target.